Company intelligence / Profile preview
Knoll
- Ownership
- Private
- Employees
- ~10000
- Development stage
- Other
Overview
Knoll was a research-driven German pharmaceutical company founded in 1886 by Albert Knoll, headquartered in Ludwigshafen. The company achieved significant medical milestones, most notably the discovery and development of verapamil, the world's first calcium channel blocker used to treat hypertension and angina. Its portfolio also included widely recognized treatments such as Synthroid for hypothyroidism and the analgesic Vicodin. In 2001, Abbott Laboratories acquired Knoll from its parent company, BASF, for $6.9 billion to strengthen its global pharmaceutical presence. Following Abbott's corporate split in 2013, Knoll's legacy products and research assets became part of AbbVie.
- Therapeutic areas
- EndocrinologyCardiovascularNeurology
- Modalities
- Small molecule
- Industry
- Pharma
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Knoll.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Knoll.